← All organizations
Highest phase reached
Phase 3
Defunct as of Jun 10, 2019
Timeline
1990s
- Jul 1, 1990
Insys Therapeutics Inc— Founded
2010s
- Nov 9, 2010
Neopharm— Acquired
- Aug 19, 2011
dronabinol— Marketing Organization
- Jul 1, 2016
dronabinol— NDA Secondary Org
- Jun 10, 2019
Insys Therapeutics Inc— Defunct
Drugs by trial phase (31 distinct, 59 trials)
Phase 3 (6 own, 0 via acquisition)
Phase 2 (6 own, 2 via acquisition)
Phase 1 (9 own, 0 via acquisition)
Other trials (3 own, 5 via acquisition)
Indications
Studied for
- Acute Pain
- Adrenocortical Carcinoma
- Amphetamine-Related Disorders
- Astrocytoma
- Breakthrough Pain
- Breast Neoplasms
- Cancer Pain
- Carcinoma
- Chronic Pain
- Dyspnea
- Emergencies
- Epilepsies, Myoclonic
- Epilepsy
- Epilepsy, Absence
- Glioblastoma
- Glioma
- Lennox Gastaut Syndrome
- Mucositis
- Neoplasms
- Oligodendroglioma
- Opioid-Related Disorders
- Pancreatic Neoplasms
- Postoperative Pain
- Prader-Willi Syndrome
- Prostatic Neoplasms
- Seizures
- Spasm
- Spasms, Infantile
- Stomatitis
- Substance-Related Disorders
- Syndrome
Marketed drugs (2)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT03458416Lead sponsorPhase 2Sep 6, 2018
- NCT03458416Study directorPhase 2Sep 6, 2018
- NCT03421496Study directorPhase 3Sep 5, 2018
- NCT03421496Lead sponsorPhase 3Sep 5, 2018
- NCT03827642Lead sponsorPhase 1Apr 23, 2018
- NCT03827642Study directorPhase 1Apr 23, 2018
- NCT03355300Study directorPhase 2Feb 20, 2018
- NCT03355300Lead sponsorPhase 2Feb 20, 2018
- NCT03336242Lead sponsorPhase 2Dec 15, 2017
- NCT03336242Study directorPhase 2Dec 15, 2017
- NCT03254459Study directorPhase 2Sep 12, 2017
- NCT03254459Lead sponsorPhase 2Sep 12, 2017
- NCT02318563Lead sponsorPhase 3Aug 31, 2017
- NCT02318563Study directorPhase 3Aug 31, 2017
- NCT03827629Study directorPhase 1Aug 7, 2017
Details
- Founded
- Chandler, AZ, US Jul 1, 1990
- Last known activity
- Sep 6, 2018